MY194308A - Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis - Google Patents

Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis

Info

Publication number
MY194308A
MY194308A MYPI2017000520A MYPI2017000520A MY194308A MY 194308 A MY194308 A MY 194308A MY PI2017000520 A MYPI2017000520 A MY PI2017000520A MY PI2017000520 A MYPI2017000520 A MY PI2017000520A MY 194308 A MY194308 A MY 194308A
Authority
MY
Malaysia
Prior art keywords
alkenyl
osteoporosis
prevention
treatment
aromatic compounds
Prior art date
Application number
MYPI2017000520A
Other languages
English (en)
Inventor
Gagnon Lyne
Grouix Brigitte
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of MY194308A publication Critical patent/MY194308A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2017000520A 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis MY194308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062597P 2014-10-10 2014-10-10
PCT/CA2015/000540 WO2016054728A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Publications (1)

Publication Number Publication Date
MY194308A true MY194308A (en) 2022-11-27

Family

ID=55652429

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017000520A MY194308A (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis

Country Status (23)

Country Link
US (2) US20180228750A1 (enExample)
EP (1) EP3203999B1 (enExample)
JP (1) JP6700639B2 (enExample)
KR (1) KR20170066476A (enExample)
CN (1) CN106999456B (enExample)
AR (1) AR102246A1 (enExample)
AU (1) AU2015330645B2 (enExample)
BR (1) BR112017007426A2 (enExample)
CA (1) CA2963354A1 (enExample)
DK (1) DK3203999T3 (enExample)
ES (1) ES2785317T3 (enExample)
IL (1) IL251404B (enExample)
MX (1) MX376873B (enExample)
MY (1) MY194308A (enExample)
PH (1) PH12017500638A1 (enExample)
PL (1) PL3203999T3 (enExample)
PT (1) PT3203999T (enExample)
RU (1) RU2709205C2 (enExample)
SG (1) SG11201702868VA (enExample)
TW (1) TWI699200B (enExample)
UY (1) UY36356A (enExample)
WO (1) WO2016054728A1 (enExample)
ZA (1) ZA201702639B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054725A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
AU2015345943B2 (en) * 2014-11-12 2020-03-19 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20190065252A (ko) * 2016-08-18 2019-06-11 인테크린 테라퓨틱스, 아이엔씨. 골 질환 치료용 PPARγ 작용제
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
AU2021356346A1 (en) * 2020-10-06 2023-06-15 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
MX2024005982A (es) * 2021-11-17 2024-05-30 Natreon Inc Withania somnifera y asparagus racemosus en el tratamiento de enfermedades posmenopausicas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200720256A (en) * 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
EP2427416B1 (en) * 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
BRPI1015118A2 (pt) * 2009-05-04 2016-04-12 Prometic Biosciences Inc sais de ácido pentilfenilacético e usos farmacêuticos dos mesmos
PH12013500763B1 (en) * 2010-10-27 2018-07-04 Prometic Pharma Smt Ltd Phenylketone carboxylate compounds and pharmaceutical uses thereof
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
WO2016054725A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Also Published As

Publication number Publication date
AR102246A1 (es) 2017-02-15
KR20170066476A (ko) 2017-06-14
BR112017007426A2 (pt) 2018-01-16
CA2963354A1 (en) 2016-04-14
TW201618762A (zh) 2016-06-01
IL251404B (en) 2020-11-30
WO2016054728A1 (en) 2016-04-14
IL251404A0 (en) 2017-05-29
PT3203999T (pt) 2020-04-23
EP3203999B1 (en) 2020-01-08
RU2017116178A (ru) 2018-11-19
DK3203999T3 (da) 2020-03-30
ZA201702639B (en) 2018-06-27
PL3203999T3 (pl) 2020-07-27
UY36356A (es) 2016-06-01
US11185521B2 (en) 2021-11-30
AU2015330645B2 (en) 2020-03-12
PH12017500638A1 (en) 2017-09-25
JP6700639B2 (ja) 2020-05-27
AU2015330645A1 (en) 2017-05-04
CN106999456B (zh) 2020-07-10
SG11201702868VA (en) 2017-05-30
RU2709205C2 (ru) 2019-12-17
MX2017004733A (es) 2017-07-17
ES2785317T3 (es) 2020-10-06
CN106999456A (zh) 2017-08-01
JP2017530180A (ja) 2017-10-12
EP3203999A4 (en) 2018-06-27
EP3203999A1 (en) 2017-08-16
MX376873B (es) 2025-03-07
TWI699200B (zh) 2020-07-21
RU2017116178A3 (enExample) 2019-05-16
US20200237693A1 (en) 2020-07-30
US20180228750A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
PH12017500638A1 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
EA032928B1 (ru) Бициклические кетосульфонамидные соединения
MY192135A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX2021001752A (es) Compuestos de pirrolo-dipiridina.
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
NZ752250A (en) Compounds, devices, and uses thereof
EA201300052A1 (ru) [1,8]нафтиридиновые производные
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
PH12015501920B1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX2015012389A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a.
PH12019501566A1 (en) Amide compounds and use thereof
WO2012077135A3 (en) Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
SG10201907026RA (en) Prevention or Treatment of Uratic or Gouty Diseases
PH12020552210A1 (en) Tricyclic compounds
PH12017500662B1 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
MY199104A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder